European shares gain with focus on healthcare M&A, Credit Suisse slips



* Unilever slides to March 2020 lows on deal move

* Credit Suisse shares drop 2% after chairman exits

* Insurer Ageas slips after Belgium take stake (Updates to market close)

By Sruthi Shankar and Ambar Warrick

Jan 17 (Reuters) - European shares closed higher on Monday, with healthcare stocks lifted by M&A activity, while Credit Suisse slipped after its chairman quit after an internal probe into his personal conduct.

The pan-European STOXX 600 index .STOXX rose 0.7% and healthcare stocks .SXDP were up 1.4%, after losing more than 2% last week, as Britain's GlaxoSmithKline GSK.L jumped 4.1%.

This followed confirmation at the weekend that the British drugmaker had rejected a 50 billion pound offer from Unilever ULVR.L for its consumer healthcare business.

Unilever shares slid 7.0% to touch March 2020 lows after it signalled on Monday it would pursue the deal, which it said represented a "strong strategic fit".

"The negative share price reaction probably reflects investor fears that Unilever is going to come back with a higher offer and potentially pay too much," said Russ Mould, investment director at AJ Bell.

Meanwhile, Credit Suisse CSGN.S shares slipped 2.3% after Chairman Antonio Horta-Osorio quit following an internal probe, including into breaches of COVID-19 rules.

New chairman Axel Lehmann said the Swiss bank will stick to its strategic overhaul despite Horta-Osorio's exit, which comes less than a year after he was hired to help it deal with the implosion of investment firm Archegos and the insolvency of British supply chain finance group Greensill Capital.

Europe's wider banking index .SX7P gained 0.2%.

"We see the resignation as a negative outcome for Credit Suisse," JPMorgan analysts said. "While the company indicates it will continue to execute its strategy, we believe the ongoing turnover with management changes brings further uncertainty."

After notching up record highs at the start of the year, trading in European stocks has hit a turbulent patch in recent days as investors priced in an aggressive tightening of U.S. monetary policy, along with a possible near-term economic slowdown caused by COVID-19.

Among individual stocks, Sabadell SABE.MC rose 4.5% after HSBC upgraded the stock to "buy" from "hold", as the brokerage sees the Spanish bank's return on equity improving at a faster pace than its peers.

EDF EDF.PA slipped 4.2%, extending losses after Friday's 15% fall as HSBC downgraded the French utility's stock, saying it will face higher costs and lower prices caused by government intervention and lower nuclear output.

Belgium's Ageas AGES.BR fell 7.4% to the bottom of the STOXX 600 after the Belgian government bought a stake, a move analysts say could signal trouble for the insurer in China.
Reporting by Sruthi Shankar in Bengaluru; Editing by Shounak Dasgupta and Alexander Smith

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.